Intravenous Immunoglobulin Market Report
RA00874
Intravenous Immunoglobulin Market, by Type (IgG, IgA, IgM, IgE, IgD), Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITP), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain–Barré Syndrome, Others): Global Opportunity Analysis and Industry Forecast, 2020-2027
The global intravenous immunoglobulin market is estimated to surpass $18,627.8 million by 2027, exhibiting a CAGR of 7.9% from 2020 to 2027.
OFFERINGS OF THE REPORT:
The report offers comprehensive analysis of the global intravenous immunoglobulin market by thoroughly studying different aspects of the market including major segments, market statistics, market dynamics, regional market outlook, investment opportunities, and top players working towards the growth of the market.
The report also sheds light on present scenario and upcoming trends and developments that are contributing in the growth of the market. In addition, key market boomers and opportunities driving the market growth are provided in the report. Besides, restraints and challenges that hold power to obstruct the market growth are also profiled in the report. The report also offers Porter’s five forces analysis of the market to elucidate factors such as competitive landscape, bargaining power of buyers and suppliers, threats of new players, and emergence of substitutes in the market.
Based on the key forces molding the market, the report offers future perspective and growth outlook of the global market. The report offers market size and forecast by keenly evaluating every segment of the global intravenous immunoglobulin market. Regional market breakdown of these segments is also offered in the report. The report divides the global intravenous immunoglobulin market into four main regions including Europe, North America, Asia-Pacific, and LAMEA. Furthermore, these regions are sub-divided to profile detailed panorama of the intravenous immunoglobulin market across major countries in specific regions. Moreover, the report reveals some of the recent developments, trends, and forthcoming opportunities in every region.
HIGHLIGHTS OF THE MARKET
- The report offers market size and forecast for the period from 2019 to 2027
- This report highlights trends, innovations, and new developments along with a detailed quantitative analysis of the intravenous immunoglobulin market during the period of forecast
- The prevailing and upcoming opportunities along with the tactical assessment of the global intravenous immunoglobulin market growth is provided
- The market size and estimations are based on a comprehensive analysis of market drivers and restraints and key innovations in the intravenous immunoglobulin market
- Information on leading market players, Porter’s Five Analysis, and top winning business strategies is offered
- The development plans and initiatives undertaken by the top market players are highlighted to understand the competitive landscape of the market
KEY MARKET SEGMENTS
The report segments the global market into type ,application
- Type: IgG, IgA, IgM, IgE, IgD
- Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITP), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain–Barré Syndrome, Others
Region:
The global intravenous immunoglobulin market is divided into North America, Europe, Asia Pacific, and LAMEA.
The above-mentioned regions are further dived in countries as follows:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA
LEADING PLAYERS OF THE MARKET
The most influential companies are mentioned in the report which include Grifols SA, Option Care Enterprises, Inc., Biotest AG, Baxter International Inc.
The report outlines the business overview including financial performance, latest strategic moves & developments, product portfolio, and SWOT analysis of the leading players of the intravenous immunoglobulin market.
1. Biotest AG
2. Baxter International Inc.
3. Octapharma AG
4. LFB Biotechnologies
5. Grifols SA
6. CSL Behring
7. China Biologics Products Inc.
8. Kedrion Biopharma
9. BDI Pharma Inc.
10. Option Care Enterprises, Inc.
RESEARCH METHODOLOGY
The report is formulated by in-house market analysts by deeply scrutinizing the market scenario. The market predictions stated in the report have been derived using proven research methodologies and analytical tools & models. Use of such advanced and effective tools, helps market analysts in scrutinizing, filtering, and offering highly accurate data and predictions. The report delivers an extensive research and analysis backed with a variety of factual data, which mainly include interviews with industry players, trustworthy and renowned sources of statistics, and regional intelligence. The insights provided in the report can help investors in understanding investment suitability and market players to grab opportunities for investments, partnerships, and developments in the global market.
The research report is formed by collating different statistics and information concerning the intravenous immunoglobulin market. For instance, around 18 hours of interviews and deliberations have been performed with a group of stakeholders and investors, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. About 5,900 product type literatures, market publications, company annual reports, and other such relevant documents of key market players have been studied, for better understanding of market penetration. Furthermore, trustworthy industry newsletters, medical journals, trade associations’ publications, and government websites have also been evaluated for extracting vital industry insights.
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Intravenous Immunoglobulin Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Intravenous Immunoglobulin Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Intravenous Immunoglobulin Market, By Product
5.1. Overview
5.2 IgG
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 IgA
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 IgM
5.4.1 Definition, key trends, growth factors, and opportunities
5.4.2 Market size analysis, by region, 2020-2027
5.4.3 Market share analysis, by country, 2020-2027
5.5 IgE
5.5.1 Definition, key trends, growth factors, and opportunities
5.5.2 Market size analysis, by region, 2020-2027
5.5.3 Market share analysis, by country, 2020-2027
5.6 IgD
5.6.1 Definition, key trends, growth factors, and opportunities
5.6.2 Market size analysis, by region, 2020-2027
5.6.3 Market share analysis, by country, 2020-2027
5.7 Research Dive Exclusive Insights
5.7.1 Market attractiveness
5.7.2 Competition heatmap
-
6. Intravenous Immunoglobulin Market, By End Use
6.1. Overview
6.2 Hypogammaglobulinemia
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Immunodeficiency Disease
6.4.1 Definition, key trends, growth factors, and opportunities
6.4.2 Market size analysis, by region, 2020-2027
6.4.3 Market share analysis, by country, 2020-2027
6.5 Myasthenia Gravis
6.5.1 Definition, key trends, growth factors, and opportunities
6.5.2 Market size analysis, by region, 2020-2027
6.5.3 Market share analysis, by country, 2020-2027
6.6 Multifocal Motor Neuropathy
6.6.1 Definition, key trends, growth factors, and opportunities
6.6.2 Market size analysis, by region, 2020-2027
6.6.3 Market share analysis, by country, 2020-2027
6.7 Idiopathic Thrombocytopenic Purpura (ITP)
6.7.1 Definition, key trends, growth factors, and opportunities
6.7.2 Market size analysis, by region, 2020-2027
6.7.3 Market share analysis, by country, 2020-2027
6.8 Inflammatory Myopathies
6.8.1 Definition, key trends, growth factors, and opportunities
6.8.2 Market size analysis, by region, 2020-2027
6.8.3 Market share analysis, by country, 2020-2027
6.9 Specific Antibody Deficiency
6.9.1 Definition, key trends, growth factors, and opportunities
6.9.2 Market size analysis, by region, 2020-2027
6.9.3 Market share analysis, by country, 2020-2027
6.10 Guillain–Barré Syndrome
6.10.1 Definition, key trends, growth factors, and opportunities
6.10.2 Market size analysis, by region, 2020-2027
6.10.3 Market share analysis, by country, 2020-2027
6.11 Others
6.11.1 Definition, key trends, growth factors, and opportunities
6.11.2 Market size analysis, by region, 2020-2027
6.11.3 Market share analysis, by country, 2020-2027
6.12 Research Dive Exclusive Insights
6.12.1 Market attractiveness
6.12.2 Competition heatmap
7. Intravenous Immunoglobulin Market, By Region
7.1 North America
7.1.1 U.S
7.1.1.1 Market size analysis, By Product, 2020-2027
7.1.1.2 Market size analysis, By End Use, 2020-2027
7.1.2 Canada
7.1.2.1 Market size analysis, By Product, 2020-2027
7.1.2.2 Market size analysis, By End Use, 2020-2027
7.1.3 Mexico
7.1.3.1 Market size analysis, By Product, 2020-2027
7.1.3.2 Market size analysis, By End Use, 2020-2027
7.1.4 Research Dive Exclusive Insights
7.1.4.1 Market attractiveness
7.1.4.2 Competition heatmap
7.2 Europe
7.2.1 Germany
7.2.1.1 Market size analysis, By Product, 2020-2027
7.2.1.2 Market size analysis, By End Use, 2020-2027
7.2.2 UK
7.2.2.1 Market size analysis, By Product, 2020-2027
7.2.2.2 Market size analysis, By End Use, 2020-2027
7.2.3 France
7.2.3.1 Market size analysis, By Product, 2020-2027
7.2.3.2 Market size analysis, By End Use, 2020-2027
7.2.4 Spain
7.2.4.1 Market size analysis, By Product, 2020-2027
7.2.4.2 Market size analysis, By End Use, 2020-2027
7.2.5 Italy
7.2.5.1 Market size analysis, By Product, 2020-2027
7.2.5.2 Market size analysis, By End Use, 2020-2027
7.2.6 Rest of Europe
7.2.6.1 Market size analysis, By Product, 2020-2027
7.2.6.2 Market size analysis, By End Use, 2020-2027
7.2.7 Research Dive Exclusive Insights
7.2.7.1 Market attractiveness
7.2.7.2 Competition heatmap
7.3 Asia-Pacific
7.3.1 China
7.3.1.1 Market size analysis, By Product, 2020-2027
7.3.1.2 Market size analysis, By End Use, 2020-2027
7.3.2 Japan
7.3.2.1 Market size analysis, By Product, 2020-2027
7.3.2.2 Market size analysis, By End Use, 2020-2027
7.3.3 India
7.3.3.1 Market size analysis, By Product, 2020-2027
7.3.3.2 Market size analysis, By End Use, 2020-2027
7.3.4 Australia
7.3.4.1 Market size analysis, By Product, 2020-2027
7.3.4.2 Market size analysis, By End Use, 2020-2027
7.3.5 South Korea
7.3.5.1 Market size analysis, By Product, 2020-2027
7.3.5.2 Market size analysis, By End Use, 2020-2027
7.3.6 Rest of Asia-Pacific
7.3.6.1 Market size analysis, By Product, 2020-2027
7.3.6.2 Market size analysis, By End Use, 2020-2027
7.3.7 Research Dive Exclusive Insights
7.3.7.1 Market attractiveness
7.3.7.2 Competition heatmap
7.4 LAMEA
7.4.1 Brazil
7.4.1.1 Market size analysis, By Product, 2020-2027
7.4.1.2 Market size analysis, By End Use, 2020-2027
7.4.2 Saudi Arabia
7.4.2.1 Market size analysis, By Product, 2020-2027
7.4.2.2 Market size analysis, By End Use, 2020-2027
7.4.3 UAE
7.4.3.1 Market size analysis, By Product, 2020-2027
7.4.3.2 Market size analysis, By End Use, 2020-2027
7.4.4 South Africa
7.4.4.1 Market size analysis, By Product, 2020-2027
7.4.4.2 Market size analysis, By End Use, 2020-2027
7.4.5 Rest of LAMEA
7.4.5.1 Market size analysis, By Product, 2020-2027
7.4.5.2 Market size analysis, By End Use, 2020-2027
7.4.6 Research Dive Exclusive Insights
7.4.6.1 Market attractiveness
7.4.6.2 Competition heatmap
8. Competitive Landscape
8.1 Top winning strategies, 2020-2027
8.1.1 By strategy
8.1.2 By year
8.2 Strategic overview
8.3 Market share analysis, 2020-2027
9. Company Profiles
9.1 Biotest AG
9.1.1 Overview
9.1.2 Business segments
9.1.3 Product portfolio
9.1.4 Financial performance
9.1.5 Recent developments
9.1.6 SWOT analysis
9.2 Baxter International Inc.
9.2.1 Overview
9.2.2 Business segments
9.2.3 Product portfolio
9.2.4 Financial performance
9.2.5 Recent developments
9.2.6 SWOT analysis
9.3 Octapharma AG
9.3.1 Overview
9.3.2 Business segments
9.3.3 Product portfolio
9.3.4 Financial performance
9.3.5 Recent developments
9.3.6 SWOT analysis
9.4 LFB Biotechnologies
9.4.1 Overview
9.4.2 Business segments
9.4.3 Product portfolio
9.4.4 Financial performance
9.4.5 Recent developments
9.4.6 SWOT analysis
9.5 Grifols SA
9.5.1 Overview
9.5.2 Business segments
9.5.3 Product portfolio
9.5.4 Financial performance
9.5.5 Recent developments
9.5.6 SWOT analysis
9.6 CSL Behring
9.6.1 Overview
9.6.2 Business segments
9.6.3 Product portfolio
9.6.4 Financial performance
9.6.5 Recent developments
9.6.6 SWOT analysis
9.7 China Biologics Products Inc.
9.7.1 Overview
9.7.2 Business segments
9.7.3 Product portfolio
9.7.4 Financial performance
9.7.5 Recent developments
9.7.6 SWOT analysis
9.8 Kedrion Biopharma
9.8.1 Overview
9.8.2 Business segments
9.8.3 Product portfolio
9.8.4 Financial performance
9.8.5 Recent developments
9.8.6 SWOT analysis
9.9 BDI Pharma Inc.
9.9.1 Overview
9.9.2 Business segments
9.9.3 Product portfolio
9.9.4 Financial performance
9.9.5 Recent developments
9.9.6 SWOT analysis
9.10 Option Care Enterprises, Inc.
9.10.1 Overview
9.10.2 Business segments
9.10.3 Product portfolio
9.10.4 Financial performance
9.10.5 Recent developments
9.10.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
